By continuing to browse this website, you consent to our use of cookies, as well as to our Terms of Use and Privacy Policy which provide additional information about how we process your data. This website uses cookies to enhance your user experience. Please read our Cookies Policy for more information on how we use cookies, as well as instructions on how to disable cookies. You may disable cookies through your internet browser settings, however this may result in some parts of the website not working properly for you.

Pharmaceutical

This function is exclusive for Premium subscribers

  • DATABASE ( 17 )
  • INSIGHTS ( 6 )

Mediktor is a clinically-approved online symptom checker, covering 90% of possible diagnoses, with an accuracy rate of 91.3%. Mediktor covers 750 diseases in 10 languages on multiple platforms, allowing free expression via voice and chatbot. The consultations are for information purposes only, not replacing diagnoses from professional medics.

China Merchants Capital (CMC), the investment management platform of China Merchants Group, was established in 2012 with a registered capital of RMB 1 billion. As of the end of 2014, it had assets under management worth nearly US$3 billion. CMC invests mainly in the infrastructure, medical & pharmaceutical, financial services, real estate, high-tech, agriculture & foods, media, equipment machinery, mining and energy sectors, among others.

Established in Shenzhen in 2007, Share Capital has invested in over 100 companies. Some of its portfolio companies – e.g., NavInfo, Perfect World and BGI – have gone public. Its investment team of nearly 50 members manages more than RMB 6 billion worth of assets. Share Capital has set up a healthcare fund of RMB 1.5 billion and invested in over 70 health-related projects.

The municipal government of Wuhan launched Wuhan S&T Angel Venture Fund in September 2013. With RMB 300 million under management, the fund is operated by Wuhan S&T Angel Venture Fund Management Co., Ltd. It invests mainly in the information technology, new materials, advanced equipment manufacturing, biomedicine, new energy, automotive, energy conservation, environmental protection and modern agriculture fields.

Alta Life Sciences (Alta LS) was established in 2016. Based in Barcelona, the management team is led by the co-founder of Alta Partners Guy Paul Nohra, a leading pioneer VC in life sciences. Alta Partners has funded over 150 companies since 1996. Alta LS specializes in the life sciences sector in Spain and abroad, targeting biotech, genomics, medical devices, diagnostics and digital health. It also acts as a bridge fund, connecting the Spanish life sciences ecosystem to VC experts in Silicon Valley. Investment is available for all stages of development, with focus mainly on seed and Series A funding.

WuXi AppTec is a Chinese company that specializes in the outsourcing of R&D in the pharmaceuticals, biotechnology and medical devices sectors. Listed on the Hong Kong Stock Exchange, WuXi AppTec has invested in drug development and healthcare firms globally. Its portfolio includes Insilico Medicine, which is developing an AI platform for drug development, brain disease research firm Verge Genomics and Indonesian healthcare platform Halodoc.

Shanghai Zhangjiang Haocheng Venture Capital Co., Ltd. (Zhangjiang Haocheng) was founded in 2007 as a wholly-owned subsidiary of listed real estate developer Shanghai Zhangjiang Hi-Tech Park Development Co., Ltd. It has invested RMB 2.5 billion in high-tech startups.

Yuexiu Industrial Fund is a fund management company founded by Yuexiu Group in Guangzhou in August 2011. It works as an investment arm of Yuexiu Group and invests mainly in emerging industries. As at November 2018, it had RMB 50 billion under its management.

Proxima Ventures was founded in 2016 in Shanghai. It manages both RMB and US dollar funds, worth around US$150m in total. The firm invests mainly in early-stage startups in the healthcare sector. It has invested in 18 companies and established six innovation centers to incubate medtech startups. 

Yueyin Venture Capital was founded in 2015 in Beijing. It manages total assets worth US$300m, with investments in 22 companies. The VC focuses mainly in the healthcare, pharmaceutical and biotech sectors. 

Haibang Fund was created in 2011 by Haibang Venture based in Hangzhou. Haibang Fund manages total assets worth US$360m with investments in 60 companies, four of which have gone public. Started by a group of overseas returnees and experienced investors, the VC focuses on startups founded by returnees from overseas.

Renhe Group was founded in Jiangxi Province by Yang Wenlong in 2001. The group, including its flagship listed Renhe Pharmacy, earned total sales revenue of RMB 11.23bn in 2018 with a year-on-year profit growth of 25%. The group comprises 20 subsidiaries dealing in cosmetics, household chemicals, pharmaceutical, medical supplies and equipment.

Junrun Capital was founded in 2009 in Ningbo, Zhejiang province. It's the largest private equity fund in Ningbo and specializes in M&A, equity and venture capital investments. So far, it has successfully exited seven deals out of a total of 21. Junrun has investment managers and researchers with backgrounds in science and technology. It has offices in Hangzhou, Shanghai, Shenzhen and the US. The company mainly seeks investment opportunities in sustainable materials, cleantech, agriculture, manufacture, biotechnology and the dotcom economy.

Founded in Beijing in 2015, Frees Fund is an asset management company with a portfolio valued at RMB 3.6bn. Frees primarily invests in early-stage startups in diverse sectors including fintech, education, healthcare, entertainment, hardware, intelligent manufacturing and SaaS. The VC is incorporated as Shanghai Ziyou Investment Management Co Ltd.

GF Qianhe is an equity investment company launched by GF Securities in May 2012. Incorporated as Guangfa Qianhe Investments Co Ltd, with a registered capital of RMB 500m, the company was one of the earliest alternative investment companies to gain approval from the Securities Commission of China. As of late 2018, GF Qianhe has invested in 86 equity-related projects, among which four have gone public. By the end of 2014, its total investment value reached almost RMB 2bn and revenues of over RMB 340m.

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download a free sample profile here to view premium content

This field is mandatory
This field is mandatory
Cancel

Download successful.

Your sample has been sent. Please check your email.